Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders

Nature

Volumn 494, Issue 7437, 2013, Pages 375-379

  Song, Ruisheng ^a,b   Peng, Wei ^a   Zhang, Yan ^a   Lv, Fengxiang ^a   Wu, Hong Kun ^a   Guo, Jiaojiao ^a   Cao, Yongxing ^c   Pi, Yanbin ^c   Zhang, Xin ^c   Jin, Li ^a   Zhang, Mao ^a   Jiang, Peng ^a   Liu, Fenghua ^a   Meng, Shaoshuai ^a   Zhang, Xiuqin ^a   Jiang, Ping ^a   Cao, Chun Mei ^a   Xiao, Rui Ping ^a  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c PEKING UNIVERSITY THIRD HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE 1; MITSUGUMIN 53; MUSCLE PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; DIABETES; DISEASE TREATMENT; ENZYME ACTIVITY; GENE EXPRESSION; GLUCOSE; HORMONE; HYPERTENSION; METABOLISM; OBESITY; PATHOGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DYSLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; MALE; METABOLIC DISORDER; MOUSE; MUSCLE STRENGTH; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

ANIMALS; CARRIER PROTEINS; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DYSLIPIDEMIAS; GENE DELETION; HYPERTENSION; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MICE; OBESITY; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

MUS;

EID: 84874189145     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11834     Document Type: Article

References (31)

1. Eckel, R. H., Grundy, S. M. & Zimmet, P. Z. The metabolic syndrome. Lancet 365, 1415-1428 (2005).
2. DeFronzo, R. A. et al. The effect of insulin on the disposal of intravenous glucose. Results fromindirect calorimetry and hepatic and femoral venous catheterization. Diabetes 30, 1000-1007 (1981).
3. Shulman, G. I. et al. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non-insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N. Engl. J. Med. 322, 223-228 (1990).
4. McMillen, I. C.& Robinson, J. S. Developmental origins of the metabolic syndrome: prediction, plasticity, and programming. Physiol. Rev. 85, 571-633 (2005).
5. Grundy, S. M. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J. Am. Coll. Cardiol. 47, 1093-1100 (2006).
6. DeFronzo, R. A. & Tripathy, D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care 32 (Suppl. 2), S157-S163 (2009).
7. Lillioja, S. et al. Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N. Engl. J. Med. 329, 1988-1992 (1993).
8. Martin, B. C. et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a25-year follow-up study. Lancet340,925-929(1992).
9. Cai, C. et al.MG53 nucleates assembly of cellmembrane repair machinery. Nature Cell Biol. 11, 56-64 (2009).
10. Cao, C. M. et al. MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation 121, 2565-2574 (2010).
11. Fu, J. et al. Oleylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-a. Nature 425, 90-93 (2003).
12. Rao, R. H. Insulin resistance in spontaneously hypertensive rats. Difference in interpretation based on insulin infusion rate or on plasmainsulin in glucose clamp studies. Diabetes 42, 1364-1371 (1993).
13. Zhang, X. et al. Rhesus macaques develop metabolic syndrome with reversible vascular dysfunction responsive to pioglitazone. Circulation 124, 77-86 (2011).
14. Coleman, D. L. Obese and diabetes: two mutant genes causing diabetes-obesity syndromes in mice. Diabetologia 14, 141-148 (1978).
15. Saltiel, A. R. & Kahn, C. R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799-806 (2001).
16. Thirone, A. C., Huang, C. & Klip, A. Tissue-specific roles of IRS proteins in insulin signaling and glucose transport. Trends Endocrinol. Metab. 17, 72-78 (2006).
17. Kerouz, N. J., Horsch, D., Pons, S. & Kahn, C. R. Differential regulation of insulin receptor substrates-1 and -2 (IRS-1 and IRS-2) and phosphatidylinositol 3-kinase isoforms in liver and muscle of the obese diabetic (ob/ob) mouse. J. Clin. Invest. 100, 3164-3172 (1997).
18. Goodyear, L. J. et al. Insulin receptor phosphorylation, insulin receptor substrate-1 phosphorylation, and phosphatidylinositol 3-kinase activity are decreased in intact skeletal muscle strips from obese subjects. J. Clin. Invest. 95, 2195-2204 (1995).
19. Olefsky, J., Bacon, V. C. & Baur, S. Insulin receptors of skeletal muscle: specific insulin binding sites and demonstration of decreased numbers of sites in obese rats. Metabolism 25, 179-191 (1976).
20. Capozza, F. et al. Caveolin-3 knockout mice show increased adiposity and whole body insulin resistance, with ligand-induced insulin receptor instability in skeletal muscle. Am. J. Physiol. Cell Physiol. 288, C1317-C1331 (2005).
21. Zisman, A. et al. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nature Med. 6, 924-928 (2000).
22. Bru? ning, J. C. et al. Amuscle-specific insulin receptor knockout exhibits features of the metabolic syndrome of NIDDM without altering glucose tolerance. Mol. Cell 2, 559-569 (1998).
23. Laustsen, P. G. et al. Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function. Mol. Cell. Biol. 27, 1649-1664 (2007).
24. Nakao, R. et al. Ubiquitin ligase Cbl-b is a negative regulator for insulin-like growth factor 1 signaling during muscle atrophy caused by unloading. Mol. Cell. Biol. 29, 4798-4811 (2009).
25. Ramos, F. J., Langlais, P. R., Hu, D., Dong, L. Q. & Liu, F. Grb10 mediates insulinstimulated degradation of the insulin receptor: A mechanism of negative regulation. Am. J. Physiol. Endocrinol. Metab. 290, E1262-E1266 (2006).
26. Rui, L., Yuan, M., Frantz, D., Shoelson, S. & White, M. F. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277, 42394-42398 (2002).
27. Xu, X. et al. The CUL7 E3 ubiquitin ligase targets insulin receptor substrate 1 for ubiquitin-dependent degradation. Mol. Cell 30, 403-414 (2008).
28. Shi, J., Luo, L., Eash, J., Ibebunjo, C.& Glass, D. J. The SCF-Fbxo40 complex induces IRS1 ubiquitination in skeletal muscle, limiting IGF1 signaling. Dev. Cell 21, 835-847 (2011).
29. Joazeiro, C. A. et al.The tyrosine kinase negative regulator c-Cbl as a RING-type, E2- dependent ubiquitin-protein ligase. Science 286, 309-312 (1999).
30. Huang, H. et al. Profiling of mismatch discrimination in RNAi enabled rational design of allele-specific siRNAs. Nucleic Acids Res. 37, 7560-7569 (2009).
31. Zhong, L. et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1a. Cell 140, 280-293 (2010).